GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...